Avalo Therapeutics, Inc. - AVTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Logos Global Management LP | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Logos Global Management GP LLC | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Logos Global Master Fund LP | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Logos GP LLC | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Arsani William | 3.2% | 1,675,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | RA Capital Management, L.P. | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | Peter Kolchinsky | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | Rajeev Shah | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 9.9% | 2,455,655 | View |
| May 15, 2026 | SCHEDULE 13G/A | OrbiMed Advisors LLC | 2.1% | 475,165 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.4% | 1,258,371 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 5.4% | 1,258,371 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 4.0% | 919,912 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 4.0% | 919,912 | View |
| May 15, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.6% | 141,562 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.6% | 141,562 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.3% | 2,178,283 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 2,347,845 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 2,347,845 | View |
| May 15, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 2,347,845 | View |
| May 15, 2026 | SCHEDULE 13G/A | Caligan Partners LP | 7.2% | 1,635,023 | View |
| May 15, 2026 | SCHEDULE 13G/A | David Johnson | 7.2% | 1,635,023 | View |
| May 15, 2026 | SCHEDULE 13G | T. Rowe Price Investment Management, Inc. | 9.5% | 2,162,684 | View |
| May 15, 2026 | SCHEDULE 13G | Avoro Capital Advisors LLC | 5.75% | 1,410,000 | View |
| May 15, 2026 | SCHEDULE 13G | Behzad Aghazadeh | 5.75% | 1,410,000 | View |
| May 14, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 5.5% | 1,340,840 | View |
| May 14, 2026 | SCHEDULE 13G/A | Michael Cho | 5.5% | 1,340,840 | View |
| May 12, 2026 | SCHEDULE 13G | TCG Crossover GP II, LLC | 7.9% | 3,017,120 | View |
| May 12, 2026 | SCHEDULE 13G | TCG Crossover Fund II, L.P. | 7.9% | 3,017,120 | View |
| May 12, 2026 | SCHEDULE 13G | Chen Yu | 7.9% | 3,017,120 | View |
| May 06, 2026 | SCHEDULE 13G/A | FMR LLC | 12.6% | 2,879,481 | View |
| May 06, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 12.6% | 2,879,481 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos Global Management LP | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos Global Management GP LLC | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos Global Master Fund LP | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Logos GP LLC | 5.6% | 1,285,000 | View |
| Apr 01, 2026 | SCHEDULE 13G | Arsani William | 5.6% | 1,285,000 | View |
| Mar 06, 2026 | SCHEDULE 13G | FMR LLC | 11.5% | 2,125,819 | View |
| Mar 06, 2026 | SCHEDULE 13G | Abigail P. Johnson | 11.5% | 2,125,819 | View |
| Feb 24, 2026 | SCHEDULE 13G | Millennium Management LLC | 5.0% | 934,429 | View |
| Feb 24, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 5.0% | 934,429 | View |
| Feb 24, 2026 | SCHEDULE 13G | Israel A. Englander | 5.0% | 934,429 | View |
| Feb 17, 2026 | SCHEDULE 13G | Millennium Management LLC | 4.8% | 887,274 | View |
| Feb 17, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 4.8% | 887,274 | View |
| Feb 17, 2026 | SCHEDULE 13G | Israel A. Englander | 4.8% | 887,274 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Caligan Partners LP | 4.9% | 881,533 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | David Johnson | 4.9% | 881,533 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Balyasny Asset Management L.P. | 2.42% | 439,312 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BAM GP LLC | 2.42% | 439,312 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Balyasny Asset Management Holdings LP | 2.42% | 439,312 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dames GP LLC | 2.42% | 439,312 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dmitry Balyasny | 2.42% | 439,312 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Management, L.P. | 9.9% | 1,939,065 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Peter Kolchinsky | 9.9% | 1,939,065 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Rajeev Shah | 9.9% | 1,939,065 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 9.9% | 1,939,065 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 3.5% | 627,502 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 3.5% | 627,502 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Steven A. Cohen | 3.5% | 627,502 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 6.8% | 1,286,909 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 6.8% | 1,286,909 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.7% | 500,507 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 2.7% | 500,507 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.5% | 97,524 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.5% | 97,524 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.4% | 1,787,416 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 1,904,257 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 1,904,257 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 1,904,257 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | OrbiMed Advisors LLC | 6.4% | 1,187,300 | View |
| Feb 10, 2026 | SCHEDULE 13G | Millennium Management LLC | 4.9% | 906,762 | View |
| Feb 10, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 4.9% | 906,762 | View |
| Feb 10, 2026 | SCHEDULE 13G | Israel A. Englander | 4.9% | 906,762 | View |
| Feb 10, 2026 | SCHEDULE 13G | SilverArc Capital Management, LLC | 2.83% | 524,436 | View |
| Feb 10, 2026 | SCHEDULE 13G | Devesh Gandhi | 2.83% | 524,436 | View |
| Feb 03, 2026 | SCHEDULE 13G | Millennium Management LLC | 4.9% | 905,798 | View |
| Feb 03, 2026 | SCHEDULE 13G | Millennium Group Management LLC | 4.9% | 905,798 | View |
| Feb 03, 2026 | SCHEDULE 13G | Israel A. Englander | 4.9% | 905,798 | View |
| Jan 30, 2026 | SCHEDULE 13G/A | The Vanguard Group | 4.43% | 804,084 | View |
| Jan 29, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 5.7% | 1,051,054 | View |
| Jan 29, 2026 | SCHEDULE 13G/A | Michael Cho | 5.7% | 1,051,054 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.